Wyeth Announces Stockholder Approval of Pfizer Merger at 2009 Annu...(sence in vaccines biologics over-the-cou...)

Date:7/20/2009

sence in vaccines, biologics, over-the-counter pharmaceuticals and infant nutritionals. Wyeth's patient-focused business units in these areas will be backed by the scale and resources of a global enterprise. We're very pleased that eight members of Wyeth's senior management team will assume significant leadership roles in R&D and commercial operations in the combined organization post closing."

At the closing of the transaction, Wyeth stockholders will be entitled to receive $33 in cash and 0.985 of a share of Pfizer common stock for each share of outstanding Wyeth stock. The transaction remains subject to necessary global regulatory approvals and other customary closing conditions. On July 17, 2009, an important condition was met when European regulators announced that they had approved the merger. A closing date for the merger has not been announced, but the companies continue to expect the transaction to close at the end of the third quarter or during the fourth quarter of this year.

Summarizing highlights from the past year, Mr. Poussot stated: "The strength and diversity of the Company we have built enabled us to achieve strong 2008 financial results, bring important new products to market, and continue to make good on our research commitment to tackle the world's most difficult diseases such as Alzheimer's and cancer. Despite a difficult economic environment and an unexpected generic attack on our third largest product, Protonix, Wyeth delivered solid financial performance with record revenues of $22.8 billion in 2008, an increase of 2%."

Wyeth also reported solid first quarter 2009 results, confirming that its long-term strategy to build one of the most diversified pharmaceutical companies is on course. By focusing on diversity by product line, by business, by technology platform and by geography, the Company generated 52% of its first quarter revenue outside the United States and 60% o
'/>"/>

SOURCE Wyeth Copyright©2009 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
2. Wyeth Announces Holder Right to Surrender Convertible Debentures
3. Wyeth Declares Common Stock Dividend
4. New Phase 3 Data Continue to Indicate that Wyeths Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
5. Wyeth Sets Webcast and Conference Call For 2009 Second Quarter Earnings
6. Wyeth Announces Full Redemption of $2 Convertible Preferred Stock
7. Wyeth Declares Common and Preferred Stock Dividends
8. Wyeth Sets Webcast and Conference Call for 2009 First Quarter Earnings
9. Wyeth to Present at the SG Cowen & Co. 29th Annual Healthcare Conference
10. Wyeth to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
11. Wyeth Names Michael Kamarck President, Technical Operations & Product Supply